Platinum Induced Fatty Acids: Are they Present in Plasma of Cancer Patients?

Vera C Mazurak, Barbara S Van der Meij, Rachel Murphy, A. Stanislaus, V. V. Damaraju, Q. Chu, Michael Sawyer

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Abstract

Rationale: Preclinical studies suggest that hexadeca-4,7,10,13-tetraenoic [16:4 (n-3)] induces resistance to platinum-based therapies. One study in healthy volunteers reported increases in 16:4(n-3) after consuming fish oil with levels returning to normal after 12 hours. No study has measured in 16:4(n-3) levels in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy.
This study aimed to determine plasma levels of 16:4(n-3) in NSCLC pts undergoing platinum-based chemotherapy in those using or not using fish oil supplements.
Methods: A method to measure 16:4(n-3) in plasma of NSCLC patients was developed and validated. Patients using fish oil (capsules or oil equivalent, n=15) and on standard of care (n=5) were selected for preliminary analysis. Plasma was prospectively collected at baseline (prior to receiving chemotherapy) and after 2 cycles of platinum-based chemotherapy. The plasma range of 16:4(n-3) at baseline and subsequently following chemotherapy were compared between those taking fish oil and those on standard of care. Plasma (80 μl) fatty acids were extracted with iso-octane, derivatized and analyzed by LC-MS/MS in positive ion mode, which enabled detection of fatty acids at <1nmol/L.
Results: At baseline, before starting chemotherapy or fish oil supplementation, all patients had detectable levels of 16:4(n-3) ranging from 8 to 160 nmol/L. Fish oil users had higher absolute values of 16:4(n-3) than standard of care (mean=47 vs 23 nmol/L; p=0.03). Changes in 16:4(n-3) concentrations after platinum based therapy were highly variable with some patients increasing and others decreasing plasma 16:4(n-3).
Conclusion: These preliminary results suggest that 16:4(n-3) may be present in NSCLC patients both before and after receiving platinum-based chemotherapy. It will be important to relate concentrations of 16:4(n-3) to chemotherapy response and survival in a larger sample of cancer patients.
Original languageEnglish
Pages (from-to)S47
Number of pages1
JournalClinical Nutrition
Volume36
Issue numberS1
DOIs
Publication statusPublished - Sep 2017
EventThe 39th European Society for Clinical Nutrition and Metabolism Congress 2017 - Hague, Netherlands
Duration: 9 Sep 201712 Sep 2017
Conference number: 39
http://www.espen.org/congress/next-congresses/12-espen/index.php?option=com_content&view=article&id=214&Itemid=1052

Fingerprint

Platinum
Fish Oils
Fatty Acids
Drug Therapy
Non-Small Cell Lung Carcinoma
Neoplasms
Standard of Care
Capsules
Healthy Volunteers
Oils
Ions
Survival
Therapeutics

Cite this

Mazurak, V. C., Van der Meij, B. S., Murphy, R., Stanislaus, A., V. Damaraju, V., Chu, Q., & Sawyer, M. (2017). Platinum Induced Fatty Acids: Are they Present in Plasma of Cancer Patients? Clinical Nutrition, 36(S1), S47. https://doi.org/10.1016/S0261-5614(17)30673-8
Mazurak, Vera C ; Van der Meij, Barbara S ; Murphy, Rachel ; Stanislaus, A. ; V. Damaraju, V. ; Chu, Q. ; Sawyer, Michael. / Platinum Induced Fatty Acids : Are they Present in Plasma of Cancer Patients?. In: Clinical Nutrition. 2017 ; Vol. 36, No. S1. pp. S47.
@article{1a3802a4b4e646afb50b3339e84998c1,
title = "Platinum Induced Fatty Acids: Are they Present in Plasma of Cancer Patients?",
abstract = "Rationale: Preclinical studies suggest that hexadeca-4,7,10,13-tetraenoic [16:4 (n-3)] induces resistance to platinum-based therapies. One study in healthy volunteers reported increases in 16:4(n-3) after consuming fish oil with levels returning to normal after 12 hours. No study has measured in 16:4(n-3) levels in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy.This study aimed to determine plasma levels of 16:4(n-3) in NSCLC pts undergoing platinum-based chemotherapy in those using or not using fish oil supplements.Methods: A method to measure 16:4(n-3) in plasma of NSCLC patients was developed and validated. Patients using fish oil (capsules or oil equivalent, n=15) and on standard of care (n=5) were selected for preliminary analysis. Plasma was prospectively collected at baseline (prior to receiving chemotherapy) and after 2 cycles of platinum-based chemotherapy. The plasma range of 16:4(n-3) at baseline and subsequently following chemotherapy were compared between those taking fish oil and those on standard of care. Plasma (80 μl) fatty acids were extracted with iso-octane, derivatized and analyzed by LC-MS/MS in positive ion mode, which enabled detection of fatty acids at <1nmol/L.Results: At baseline, before starting chemotherapy or fish oil supplementation, all patients had detectable levels of 16:4(n-3) ranging from 8 to 160 nmol/L. Fish oil users had higher absolute values of 16:4(n-3) than standard of care (mean=47 vs 23 nmol/L; p=0.03). Changes in 16:4(n-3) concentrations after platinum based therapy were highly variable with some patients increasing and others decreasing plasma 16:4(n-3).Conclusion: These preliminary results suggest that 16:4(n-3) may be present in NSCLC patients both before and after receiving platinum-based chemotherapy. It will be important to relate concentrations of 16:4(n-3) to chemotherapy response and survival in a larger sample of cancer patients.",
author = "Mazurak, {Vera C} and {Van der Meij}, {Barbara S} and Rachel Murphy and A. Stanislaus and {V. Damaraju}, V. and Q. Chu and Michael Sawyer",
year = "2017",
month = "9",
doi = "10.1016/S0261-5614(17)30673-8",
language = "English",
volume = "36",
pages = "S47",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "S1",

}

Mazurak, VC, Van der Meij, BS, Murphy, R, Stanislaus, A, V. Damaraju, V, Chu, Q & Sawyer, M 2017, 'Platinum Induced Fatty Acids: Are they Present in Plasma of Cancer Patients?' Clinical Nutrition, vol. 36, no. S1, pp. S47. https://doi.org/10.1016/S0261-5614(17)30673-8

Platinum Induced Fatty Acids : Are they Present in Plasma of Cancer Patients? / Mazurak, Vera C; Van der Meij, Barbara S; Murphy, Rachel; Stanislaus, A.; V. Damaraju, V.; Chu, Q. ; Sawyer, Michael.

In: Clinical Nutrition, Vol. 36, No. S1, 09.2017, p. S47.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - Platinum Induced Fatty Acids

T2 - Are they Present in Plasma of Cancer Patients?

AU - Mazurak, Vera C

AU - Van der Meij, Barbara S

AU - Murphy, Rachel

AU - Stanislaus, A.

AU - V. Damaraju, V.

AU - Chu, Q.

AU - Sawyer, Michael

PY - 2017/9

Y1 - 2017/9

N2 - Rationale: Preclinical studies suggest that hexadeca-4,7,10,13-tetraenoic [16:4 (n-3)] induces resistance to platinum-based therapies. One study in healthy volunteers reported increases in 16:4(n-3) after consuming fish oil with levels returning to normal after 12 hours. No study has measured in 16:4(n-3) levels in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy.This study aimed to determine plasma levels of 16:4(n-3) in NSCLC pts undergoing platinum-based chemotherapy in those using or not using fish oil supplements.Methods: A method to measure 16:4(n-3) in plasma of NSCLC patients was developed and validated. Patients using fish oil (capsules or oil equivalent, n=15) and on standard of care (n=5) were selected for preliminary analysis. Plasma was prospectively collected at baseline (prior to receiving chemotherapy) and after 2 cycles of platinum-based chemotherapy. The plasma range of 16:4(n-3) at baseline and subsequently following chemotherapy were compared between those taking fish oil and those on standard of care. Plasma (80 μl) fatty acids were extracted with iso-octane, derivatized and analyzed by LC-MS/MS in positive ion mode, which enabled detection of fatty acids at <1nmol/L.Results: At baseline, before starting chemotherapy or fish oil supplementation, all patients had detectable levels of 16:4(n-3) ranging from 8 to 160 nmol/L. Fish oil users had higher absolute values of 16:4(n-3) than standard of care (mean=47 vs 23 nmol/L; p=0.03). Changes in 16:4(n-3) concentrations after platinum based therapy were highly variable with some patients increasing and others decreasing plasma 16:4(n-3).Conclusion: These preliminary results suggest that 16:4(n-3) may be present in NSCLC patients both before and after receiving platinum-based chemotherapy. It will be important to relate concentrations of 16:4(n-3) to chemotherapy response and survival in a larger sample of cancer patients.

AB - Rationale: Preclinical studies suggest that hexadeca-4,7,10,13-tetraenoic [16:4 (n-3)] induces resistance to platinum-based therapies. One study in healthy volunteers reported increases in 16:4(n-3) after consuming fish oil with levels returning to normal after 12 hours. No study has measured in 16:4(n-3) levels in non-small cell lung cancer (NSCLC) patients receiving platinum based chemotherapy.This study aimed to determine plasma levels of 16:4(n-3) in NSCLC pts undergoing platinum-based chemotherapy in those using or not using fish oil supplements.Methods: A method to measure 16:4(n-3) in plasma of NSCLC patients was developed and validated. Patients using fish oil (capsules or oil equivalent, n=15) and on standard of care (n=5) were selected for preliminary analysis. Plasma was prospectively collected at baseline (prior to receiving chemotherapy) and after 2 cycles of platinum-based chemotherapy. The plasma range of 16:4(n-3) at baseline and subsequently following chemotherapy were compared between those taking fish oil and those on standard of care. Plasma (80 μl) fatty acids were extracted with iso-octane, derivatized and analyzed by LC-MS/MS in positive ion mode, which enabled detection of fatty acids at <1nmol/L.Results: At baseline, before starting chemotherapy or fish oil supplementation, all patients had detectable levels of 16:4(n-3) ranging from 8 to 160 nmol/L. Fish oil users had higher absolute values of 16:4(n-3) than standard of care (mean=47 vs 23 nmol/L; p=0.03). Changes in 16:4(n-3) concentrations after platinum based therapy were highly variable with some patients increasing and others decreasing plasma 16:4(n-3).Conclusion: These preliminary results suggest that 16:4(n-3) may be present in NSCLC patients both before and after receiving platinum-based chemotherapy. It will be important to relate concentrations of 16:4(n-3) to chemotherapy response and survival in a larger sample of cancer patients.

U2 - 10.1016/S0261-5614(17)30673-8

DO - 10.1016/S0261-5614(17)30673-8

M3 - Meeting Abstract

VL - 36

SP - S47

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - S1

ER -